AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34451039 — intervention group
Group type: COMPARATOR
Intervention: Walking exercise
Number of subjects: 71
Study 32302682 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative tangential whole breast radiation therapy (RT)
Number of subjects: 1187
Study 32302682 — intervention group
Group type: COMPARATOR
Intervention: No further treatment (Control group)
Number of subjects: 1187
Study 35048156 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Resistance Training (PRT)
Number of subjects: 109
Study 35048156 — intervention group
Group type: COMPARATOR
Intervention: Non-PRT
Number of subjects: 109
Study 32784412 — intervention group
Group type: EXPERIMENTAL
Intervention: High-gamma-polyglutamic acid (HPGA) natto (439.6 mg of γ-PGA)
Number of subjects: 36
Study 32784412 — intervention group
Group type: COMPARATOR
Intervention: Low-gamma-polyglutamic acid (LPGA) natto (57.6 mg of γ-PGA)
Number of subjects: 36
Study 35555447 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (Oculus Quest 2TM)
Number of subjects: 0
Study 35555447 — intervention group
Group type: EXPERIMENTAL
Intervention: AlioscopyTM
Number of subjects: 0
Study 35555447 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical 3D-printed bone model
Number of subjects: 0
Study 32293798 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus 115 mg weekly and perifosine 100 mg daily (following 600 mg load)
Number of subjects: 35
Study 32293798 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus 50 mg (dose level 3)
Number of subjects: 35
Study 32293798 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus 170 mg (dose level 7)
Number of subjects: 35
Study 32293798 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus 170 mg (dose level 6)
Number of subjects: 35
Study 32293798 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus (various doses)
Number of subjects: 35
Study 32268867 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin U‐500
Number of subjects: 0
Study 36152381 — intervention group
Group type: EXPERIMENTAL
Intervention: Estratetraenol
Number of subjects: 76
Study 36152381 — intervention group
Group type: COMPARATOR
Intervention: Control carrier
Number of subjects: 76
Study 33733339 — intervention group
Group type: EXPERIMENTAL
Intervention: Stearic acid-rich meals
Number of subjects: 32
Study 33733339 — intervention group
Group type: COMPARATOR
Intervention: Palmitic acid-rich meals
Number of subjects: 32
Study 32147078 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 IU alpha-tocopherol soft gels (200 IU three times daily)
Number of subjects: 49
Study 32147078 — intervention group
Group type: COMPARATOR
Intervention: Placebo soft gels
Number of subjects: 49
Study 36364888 — intervention group
Group type: EXPERIMENTAL
Intervention: Tritordeum-Based Diet (TBD)
Number of subjects: 38
Study 36364888 — intervention group
Group type: COMPARATOR
Intervention: Low-FODMAPs Diet (LFD)
Number of subjects: 38
Study 36364888 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TBD and LFD
Number of subjects: 38
Study 33768237 — intervention group
Group type: EXPERIMENTAL
Intervention: Secnidazole 2 g single oral dose
Number of subjects: 100
Study 33768237 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 36281743 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training
Number of subjects: 43
Study 36281743 — intervention group
Group type: COMPARATOR
Intervention: Relaxation training
Number of subjects: 43
Study 32960456 — intervention group
Group type: EXPERIMENTAL
Intervention: Management toolkit
Number of subjects: 131
Study 32960456 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 131
Study 35820337 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamers asked about their playing habits prior to the study
Number of subjects: 121
Study 35820337 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-gamers asked about their playing habits prior to the study
Number of subjects: 121
Study 35820337 — intervention group
Group type: COMPARATOR
Intervention: Gamers asked about their playing habits following the study
Number of subjects: 121
Study 35820337 — intervention group
Group type: COMPARATOR
Intervention: Non-gamers asked about their playing habits following the study
Number of subjects: 121
Study 33772502 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental day exercise (after maximal incremental test)
Number of subjects: 39
Study 33772502 — intervention group
Group type: COMPARATOR
Intervention: Control (non-exercise)
Number of subjects: 39
Study 32935529 — intervention group
Group type: EXPERIMENTAL
Intervention: GLB plus nutrigenomics
Number of subjects: 140
Study 32935529 — intervention group
Group type: COMPARATOR
Intervention: Standard GLB program
Number of subjects: 140
Study 35246585 — intervention group
Group type: EXPERIMENTAL
Intervention: HR+/HER2+ subtype patients
Number of subjects: 4310
Study 35246585 — intervention group
Group type: EXPERIMENTAL
Intervention: HR-/HER2- subtype patients
Number of subjects: 4310
Study 35493455 — intervention group
Group type: EXPERIMENTAL
Intervention: mepolizumab 300 mg subcutaneously every 4 weeks for 32 weeks
Number of subjects: 0
Study 35493455 — intervention group
Group type: EXPERIMENTAL
Intervention: mepolizumab
Number of subjects: 0
Study 35493455 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 32701512 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole plus estradiol (E2)
Number of subjects: 0
Study 32701512 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole
Number of subjects: 0
Study 32701512 — intervention group
Group type: COMPARATOR
Intervention: Exemestane
Number of subjects: 0
Study 32701512 — intervention group
Group type: COMPARATOR
Intervention: Letrozole
Number of subjects: 0
Study 36113708 — intervention group
Group type: EXPERIMENTAL
Intervention: Craniosacral therapy (CST) sessions (1-3 sessions until symptoms resolved)
Number of subjects: 58
Study 36113708 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 58
Study 33956873 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructor-led distance learning (DL)
Number of subjects: 62
Study 33956873 — intervention group
Group type: COMPARATOR
Intervention: Conventional learning (CL)
Number of subjects: 62
Study 32025522 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean Red Ginseng (KRG)
Number of subjects: 61
Study 32025522 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 33561085 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval running test (8 bouts of 3 min at 85% of maximal aerobic speed)
Number of subjects: 104
Study 33561085 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric-based resistance exercise protocol (10 sets of 10 repetitions of plate-loaded barbell parallel back squats at 60% of 1RM)
Number of subjects: 104
Study 33831317 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO-deficit (treadmill exercise followed by a non-caloric, taste-matched placebo)
Number of subjects: 9
Study 33831317 — intervention group
Group type: COMPARATOR
Intervention: CHO-replace (treadmill exercise followed by a carbohydrate replacement drink of 200 or 150 g maltodextrin)
Number of subjects: 9
Study 33831317 — intervention group
Group type: COMPARATOR
Intervention: Rest (seated rest with no drink provided)
Number of subjects: 9
Study 36122810 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingesting 75-g glucose
Number of subjects: 44
Study 36122810 — intervention group
Group type: EXPERIMENTAL
Intervention: People with excess fat mass
Number of subjects: 44
Study 36122810 — intervention group
Group type: EXPERIMENTAL
Intervention: High blood glucose or excess body fat
Number of subjects: 44
Study 33308893 — intervention group
Group type: EXPERIMENTAL
Intervention: Aging and Engaging Program (AEP) - web-based communication coach, delivered with minimal assistance in the home (eight brief sessions over 4–6 weeks)
Number of subjects: 20
Study 33308893 — intervention group
Group type: COMPARATOR
Intervention: Control - education and videos on communication
Number of subjects: 20
Study 35932992 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral neurofeedback training
Number of subjects: 14
Study 35932992 — intervention group
Group type: COMPARATOR
Intervention: Ipsilateral neurofeedback training
Number of subjects: 14
Study 32008886 — intervention group
Group type: EXPERIMENTAL
Intervention: TrueBeam (TB)
Number of subjects: 3
Study 32008886 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinac V4
Number of subjects: 3
Study 32008886 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinac V5
Number of subjects: 3
Study 32008886 — intervention group
Group type: COMPARATOR
Intervention: Clinacs (V4 and V5)
Number of subjects: 3
Study 35556054 — intervention group
Group type: EXPERIMENTAL
Intervention: BH4 (Sapropterin, 10 mg/kg)
Number of subjects: 5
Study 35556054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 32342496 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabiximols (oromucosal cannabinoid medicine), 12 sprays/day max based on clinical response/tolerability for 12 weeks
Number of subjects: 72
Study 32342496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 32342496 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabiximols
Number of subjects: 72
Study 35606184 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative nutritional supplements
Number of subjects: 71
Study 35606184 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 71
Study 33887881 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training (CT) group
Number of subjects: 64
Study 33887881 — intervention group
Group type: COMPARATOR
Intervention: Routine training (RT) group
Number of subjects: 64
Study 35963411 — intervention group
Group type: EXPERIMENTAL
Intervention: Traffic-related air pollution exposure (main road)
Number of subjects: 35
Study 35963411 — intervention group
Group type: COMPARATOR
Intervention: Traffic-free park exposure
Number of subjects: 35
Study 33483840 — intervention group
Group type: EXPERIMENTAL
Intervention: SW-1 (200 kg)
Number of subjects: 20
Study 33483840 — intervention group
Group type: EXPERIMENTAL
Intervention: SW-2 (250 kg)
Number of subjects: 20
Study 33483840 — intervention group
Group type: EXPERIMENTAL
Intervention: SW-3 (300 kg)
Number of subjects: 20
Study 33483840 — intervention group
Group type: EXPERIMENTAL
Intervention: SW-4 (350 kg)
Number of subjects: 20
Study 33426079 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel Rhythmic Physical Activities (NRPA)
Number of subjects: 289
Study 33426079 — intervention group
Group type: COMPARATOR
Intervention: Traditional Rhythmic Physical Activities (TRPA)
Number of subjects: 289
Study 36286574 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized Photobiomodulation (PBMT) applied using 850 nm with continuous wave, total of 526-1402 J each session, twice a week for 5 weeks
Number of subjects: 31
Study 36286574 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized Photobiomodulation (PBMT)
Number of subjects: 31
Study 36286574 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (sham irradiation)
Number of subjects: 31
Study 33237990 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-exercise group (8-week mindfulness intervention + 18 weeks exercise therapy, 3 sessions/week)
Number of subjects: 30
Study 33237990 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-exercise group
Number of subjects: 30
Study 33237990 — intervention group
Group type: COMPARATOR
Intervention: Exercise-only group (18 weeks exercise therapy, 3 sessions/week)
Number of subjects: 30
Study 32915638 — intervention group
Group type: EXPERIMENTAL
Intervention: 6,400 IU/day vitamin D3
Number of subjects: 419
Study 32915638 — intervention group
Group type: EXPERIMENTAL
Intervention: 2,400 IU/day vitamin D3
Number of subjects: 419
Study 32915638 — intervention group
Group type: COMPARATOR
Intervention: 400 IU/day vitamin D3
Number of subjects: 419
Study 32915638 — intervention group
Group type: COMPARATOR
Intervention: Placebo for infants in 2,400 and 6,400 IU groups
Number of subjects: 419
Study 33774458 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15−0.2 mg/kg nalbuphine
Number of subjects: 30
Study 33774458 — intervention group
Group type: COMPARATOR
Intervention: 0.75–1.0 mg/kg tramadol
Number of subjects: 30
Study 35227795 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular recanalization with stenting (EI)
Number of subjects: 238
Study 35227795 — intervention group
Group type: COMPARATOR
Intervention: Remote endarterectomy (RE)
Number of subjects: 238
Study 35227795 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular reintervention (EI)
Number of subjects: 238
Study 35227795 — intervention group
Group type: COMPARATOR
Intervention: Endovascular reintervention (RE)
Number of subjects: 238
Study 32692747 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of BMIGPS
Number of subjects: 397
Study 32692747 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of BMICNS
Number of subjects: 397
Study 32692747 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of BMInon-CNS
Number of subjects: 397
Study 34001096 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum CFP-10 signal in HIV-infected infants
Number of subjects: 519
Study 34001096 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum CFP-10 signal in HIV-uninfected infants
Number of subjects: 519
Study 34001096 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum CFP-10 signal for confirmed and unconfirmed TB
Number of subjects: 519
Study 34605188 — intervention group
Group type: EXPERIMENTAL
Intervention: TEENS+parent weight loss (PWL; adult behavioural weight loss)
Number of subjects: 82
Study 34605188 — intervention group
Group type: COMPARATOR
Intervention: TEENS+parents as coaches (PAC; parent skills training)
Number of subjects: 82
Study 34605188 — intervention group
Group type: EXPERIMENTAL
Intervention: TEENS+parent weight loss (PWL) during maintenance
Number of subjects: 82
Study 34605188 — intervention group
Group type: COMPARATOR
Intervention: TEENS+parents as coaches (PAC) during maintenance
Number of subjects: 82
Study 34241688 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination method cohort using contrast-enhanced ultrasonography (CEUS) and blue dye (BD) together
Number of subjects: 144
Study 34241688 — intervention group
Group type: COMPARATOR
Intervention: Single BD method cohort
Number of subjects: 144
Study 34241688 — intervention group
Group type: EXPERIMENTAL
Intervention: CEUS for SLN diagnosis
Number of subjects: 144
Study 34241688 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination method cohort
Number of subjects: 144
Study 34241688 — intervention group
Group type: EXPERIMENTAL
Intervention: Both cohorts
Number of subjects: 144
Study 34818112 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 945
Study 34818112 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab alone
Number of subjects: 945
Study 34818112 — intervention group
Group type: COMPARATOR
Intervention: Ipilimumab
Number of subjects: 945
Study 35582875 — intervention group
Group type: EXPERIMENTAL
Intervention: Directly observed therapy (DOT)
Number of subjects: 110
Study 35582875 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortnightly provision
Number of subjects: 110
Study 35582875 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortnightly provision with psychological intervention
Number of subjects: 110
Study 35582875 — intervention group
Group type: COMPARATOR
Intervention: Comparison of all groups
Number of subjects: 110
Study 33290737 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 328
Study 33290737 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 328
Study 33590471 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (OXC) monotherapy
Number of subjects: 70
Study 33590471 — intervention group
Group type: COMPARATOR
Intervention: Levetiracetam (LEV) monotherapy
Number of subjects: 70
Study 35086969 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimos™ sphincterotome
Number of subjects: 104
Study 35086969 — intervention group
Group type: COMPARATOR
Intervention: CleverCut3™ sphincterotome
Number of subjects: 104
Study 34444711 — intervention group
Group type: EXPERIMENTAL
Intervention: Berberine (500 mg orally, twice a day)
Number of subjects: 84
Study 34444711 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 36006437 — intervention group
Group type: EXPERIMENTAL
Intervention: (chemo)radiotherapy with larynx V50Gy exceeding 53%
Number of subjects: 61
Study 36006437 — intervention group
Group type: EXPERIMENTAL
Intervention: (chemo)radiotherapy
Number of subjects: 61
Study 32433377 — intervention group
Group type: EXPERIMENTAL
Intervention: Microlearning wellness interventions
Number of subjects: 0
Study 32433377 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 36256695 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 3239
Study 36256695 — intervention group
Group type: COMPARATOR
Intervention: Prasugrel
Number of subjects: 3239
Study 36256695 — intervention group
Group type: EXPERIMENTAL
Intervention: HBR status
Number of subjects: 3239
Study 34424907 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-based screening
Number of subjects: 395725
Study 34424907 — intervention group
Group type: COMPARATOR
Intervention: Cytology-based screening
Number of subjects: 395725
Study 32598941 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS over the right DLPFC
Number of subjects: 60
Study 32598941 — intervention group
Group type: COMPARATOR
Intervention: Sham-tDCS (placebo)
Number of subjects: 60
Study 33136770 — intervention group
Group type: EXPERIMENTAL
Intervention: Rowing
Number of subjects: 22
Study 33136770 — intervention group
Group type: COMPARATOR
Intervention: Cycling
Number of subjects: 22
Study 32316918 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio distraction
Number of subjects: 289
Study 32316918 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual distraction
Number of subjects: 289
Study 32316918 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of audio and visual distraction
Number of subjects: 289
Study 32316918 — intervention group
Group type: COMPARATOR
Intervention: Control group (no distraction)
Number of subjects: 289
Study 35471708 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEK cages
Number of subjects: 104
Study 35471708 — intervention group
Group type: COMPARATOR
Intervention: TC-PEEK cages
Number of subjects: 104
Study 35118794 — intervention group
Group type: EXPERIMENTAL
Intervention: Shaken baby syndrome prevention program (SBSPP)
Number of subjects: 87
Study 35118794 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 87
Study 34127362 — intervention group
Group type: EXPERIMENTAL
Intervention: VidaTalk™ application
Number of subjects: 7
Study 32379695 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist-ankle acupuncture (WAA) combined with auricular acupuncture (AA)
Number of subjects: 160
Study 32379695 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist-ankle acupuncture (WAA)
Number of subjects: 160
Study 32379695 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture (AA)
Number of subjects: 160
Study 32379695 — intervention group
Group type: COMPARATOR
Intervention: Conventional analgesia alone (Control Group A)
Number of subjects: 160
Study 32379695 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist-ankle acupuncture (WAA) + Conventional analgesia (Control Group B)
Number of subjects: 160
Study 32379695 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture (AA) + Conventional analgesia (Control Group C)
Number of subjects: 160
Study 32379695 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist-ankle acupuncture (WAA) + Auricular acupuncture (AA) + Conventional analgesia (Control Group D)
Number of subjects: 160
Study 34648051 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomograms predicting overall survival (OS) and cancer-specific survival (CSS)
Number of subjects: 864
Study 34648051 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk group
Number of subjects: 864
Study 34648051 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-risk group
Number of subjects: 864
Study 33272244 — intervention group
Group type: EXPERIMENTAL
Intervention: MASS intervention
Number of subjects: 200
Study 34847710 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-stage consent process
Number of subjects: 2325
Study 34847710 — intervention group
Group type: EXPERIMENTAL
Intervention: Doctor consent
Number of subjects: 2325
Study 34847710 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative consent
Number of subjects: 2325
Study 34847710 — intervention group
Group type: COMPARATOR
Intervention: 1-stage consent
Number of subjects: 2325
Study 34847710 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-stage pathways
Number of subjects: 2325
Study 34529073 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant women with PCOS
Number of subjects: 358
Study 34529073 — intervention group
Group type: COMPARATOR
Intervention: Pregnant women without PCOS (controls)
Number of subjects: 358
Study 33827105 — intervention group
Group type: EXPERIMENTAL
Intervention: PHQ-9 score decreases of 7-9 points
Number of subjects: 906
Study 33827105 — intervention group
Group type: EXPERIMENTAL
Intervention: PHQ-9 score decreases of 14-16 points
Number of subjects: 906
Study 33827105 — intervention group
Group type: EXPERIMENTAL
Intervention: Univariate analyses of 9 depression treatment metrics
Number of subjects: 906
Study 33827105 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate models
Number of subjects: 906
Study 33827105 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute score change of 8 points or greater in PHQ-9
Number of subjects: 906
Study 32434637 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum stretcher combined with feeding
Number of subjects: 80
Study 32434637 — intervention group
Group type: COMPARATOR
Intervention: Conventional sedation
Number of subjects: 80
Study 36106652 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin icodec
Number of subjects: 6
Study 36106652 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine U100 or U300 or insulin degludec
Number of subjects: 6
Study 35503653 — intervention group
Group type: COMPARATOR
Intervention: Text messaging-based mindfulness intervention for insomnia
Number of subjects: 919
Study 35503653 — intervention group
Group type: COMPARATOR
Intervention: Text messaging-based mindfulness intervention for pain
Number of subjects: 919